VYNE Therapeutics (VYNE) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on VYNE Therapeutics (VYNEResearch Report) on June 17 and set a price target of $7.00. The company’s shares closed last Friday at $0.51, close to its 52-week low of $0.34.

According to, Pantginis is ranked 0 out of 5 stars with an average return of -32.6% and a 17.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for VYNE Therapeutics with a $8.50 average price target.

See the top stocks recommended by analysts >>

VYNE Therapeutics’ market cap is currently $29.48M and has a P/E ratio of -0.44.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.

Read More on VYNE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More